{
    "clinical_study": {
        "@rank": "122640", 
        "arm_group": [
            {
                "arm_group_label": "Placebo t.i.d.", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo t.i.d."
            }, 
            {
                "arm_group_label": "YJP-14 25 mg t.i.d.", 
                "arm_group_type": "Placebo Comparator", 
                "description": "YJP-14 25 mg t.i.d. YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems."
            }, 
            {
                "arm_group_label": "YJP-14 50 mg t.i.d.", 
                "arm_group_type": "Placebo Comparator", 
                "description": "YJP-14 50 mg t.i.d. YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems."
            }, 
            {
                "arm_group_label": "YJP-14 100 mg t.i.d.", 
                "arm_group_type": "Placebo Comparator", 
                "description": "YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems. YJP-14 100 mg t.i.d."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and efficacy of YJP-14 capsules for the\n      treatment of endothelial dysfunction in patients with diabetes mellitus."
        }, 
        "brief_title": "YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes Mellitus", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetic Complication", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Complications"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary purpose of this study is to demonstrate superior effect of YJP-14 three doses,\n      25, 50 and 100 mg t.i.d on endothelial dysfunction in diabetes mellitus indicated as pooled\n      mean change difference of flow-mediated dilation (FMD), compared to placebo group after\n      treatment of 12 weeks.\n\n      The secondary purposes of this study are divided into three as following ;\n\n      The first secondary purpose of this study is to evaluate clinically significant effect of\n      YJP-14 three doses, 25, 50 and 100 mg t.i.d on endothelial dysfunction in diabetes mellitus\n      indicated as pooled mean change difference of FMD, compared to placebo group after treatment\n      of 4-weeks and 8-weeks.\n\n      The second secondary purpose of this study is to evaluate clinically significant effect of\n      YJP-14 three doses, 25, 50 and 100 mg t.i.d on insulin resistance in diabetes mellitus\n      indicated as pooled mean change difference of Homeostasis Model Assessment-Insulin\n      Resistance (HOMA-IR), compared to placebo group after treatment of 4-weeks, 8-weeks and\n      12-weeks.\n\n      The third secondary purpose of this study is to evaluate clinically significant effect of\n      YJP-14 three doses, 25, 50 and 100 mg t.i.d on pooled mean change difference of blood\n      pressure in diabetes mellitus, compared to placebo group after treatment of 4-weeks, 8-weeks\n      and 12-weeks.\n\n      The exploratory purposes of this study are divided into two as following ;\n\n      The first exploratory purpose of this study is to evaluate clinically significant effect of\n      YJP-14 three doses, 25, 50 and 100 mg t.i.d on blood glucose level in diabetes mellitus\n      indicated as pooled mean change difference of HbA1c, compared to placebo group after\n      treatment of 12-weeks.\n\n      The second exploratory purpose of this study is to evaluate clinically significant effect of\n      YJP-14 three doses, 25, 50 and 100 mg t.i.d on vascular stiffness in diabetes mellitus\n      indicated as pooled mean change difference of blood lipids, LDL, HDL and TG, compared to\n      placebo group after treatment of 12-weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Adult onset DM defined as fasting glucose greater than 125 mg/dl or by ongoing treatment\n        with an oral hypoglycemic agent Endothelial dysfunction: FMD 5% below LDL cholesterol\n        level less than 140 mg/dl Patients agreed to Informed Consent Form\n\n        Exclusion Criteria: (Key exclusion criteria) Uncontrolled arterial hypertension (above\n        130/90 mmHg)or hypotension (below 80/50 mmHg) Severe diabetic complication : diabetic\n        nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic vascular complications"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "136", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01836172", 
            "org_study_id": "HW2012-YJP002"
        }, 
        "intervention": {
            "arm_group_label": [
                "Placebo t.i.d.", 
                "YJP-14 25 mg t.i.d.", 
                "YJP-14 50 mg t.i.d.", 
                "YJP-14 100 mg t.i.d."
            ], 
            "description": "An 50% ethanolic extract of Lindera obtusiloba stems", 
            "intervention_name": "YJP-14", 
            "intervention_type": "Drug", 
            "other_name": "An 50% ethanolic extract of Lindera obtusiloba stems"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "The treatment of diabetic complication", 
        "lastchanged_date": "July 9, 2013", 
        "location": {
            "contact": {
                "email": "ohbhmed@snu.ac.kr", 
                "last_name": "Byung-Hee Oh, M.D., Ph.D.", 
                "phone": "+82-2-2072-3345"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "110-744"
                }, 
                "name": "Internal medicine, Seoul National University Hospital"
            }, 
            "investigator": {
                "last_name": "Byung-Hee Oh, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "Multicenter, Randomized, Double Blind, Placebo-controlled, Phase II Clinical Trial to Evaluate the Safety and Efficacy of YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes Mellitus", 
        "other_outcome": {
            "description": "Pooled mean change difference of HbA1c for 12 weeks Pooled mean change difference of serum lipids (LDL, HDL and TG) for 12 weeks", 
            "measure": "HbA1c  Serum lipids (LDL, HDL and TG)", 
            "safety_issue": "No", 
            "time_frame": "12-weeks"
        }, 
        "overall_contact": {
            "email": "leejungok@hwpharm.com", 
            "last_name": "Jung-Ok LEE, Ph.D.", 
            "phone": "+82-10-2867-6905"
        }, 
        "overall_contact_backup": {
            "email": "hsmoon@hwpharm.com", 
            "last_name": "Hong-sik MOON, Ph.D.", 
            "phone": "+82-10-6482-2130"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Byung-Hee Oh, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Pooled mean change difference of Flow-mediated dilation (FMD) for 12 weeks", 
            "measure": "Flow-mediated dilation (FMD)", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "reference": [
            {
                "PMID": "21533989", 
                "citation": "Lee JO, Oak MH, Jung SH, Park DH, Auger C, Kim KR, Lee SW, Schini-Kerth VB. An ethanolic extract of Lindera obtusiloba stems causes NO-mediated endothelium-dependent relaxations in rat aortic rings and prevents angiotensin II-induced hypertension and endothelial dysfunction in rats. Naunyn Schmiedebergs Arch Pharmacol. 2011 Jun;383(6):635-45. doi: 10.1007/s00210-011-0643-9. Epub 2011 May 2."
            }, 
            {
                "PMID": "23755196", 
                "citation": "Lee JO, Auger C, Park DH, Kang M, Oak MH, Kim KR, Schini-Kerth VB. An Ethanolic Extract of Lindera obtusiloba Stems, YJP-14, Improves Endothelial Dysfunction, Metabolic Parameters and Physical Performance in Diabetic db/db Mice. PLoS One. 2013 Jun 3;8(6):e65227. doi: 10.1371/journal.pone.0065227. Print 2013."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01836172"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Pooled mean change difference of Flow-mediated dilation (FMD) for 4 and 8 weeks Pooled mean change difference of Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) for 4, 8 and 12 weeks Pooled mean change difference of Systolic and Diastolic Blood Pressure for 4, 8 and 12 weeks", 
            "measure": "Flow-mediated dilation (FMD) Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) Systolic and Diastolic Blood Pressure", 
            "safety_issue": "No", 
            "time_frame": "4, 8 and 12-weeks"
        }, 
        "source": "Han Wha Pharma Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Han Wha Pharma Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}